Thank you, Madam Co-Chair.
Dr. Pereira, I'd like to start with you. In the previous panel, we had a witness from TheraPsil who was talking about the research that's going on in Johns Hopkins University into psilocybin therapy used in a very controlled environment with cognitive behavioural therapy. One of my own constituents, palliative care physician Dr. Valorie Masuda, has been granted access to this through special exemptions from Health Canada, and she has reported remarkable success in helping patients who are in palliative care overcome their anxiety.
Do you have any thoughts to offer on this research?
There have been calls not only for additional funding into the research, but also to tackle Health Canada's overly complicated and restrictive rules. I want you to answer this in the theme of a patient-centred approach, if we are trying to help patients at the end of their life in palliative care meet their end in a safe and controlled way such that they are not filled with anxiety.
Do you have any thoughts on this?